Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

NCT06588283 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether combining ixekizumab and tirzepatide can help adults with moderate-to-severe plaque psoriasis and obesity or overweight achieve clear skin and lose at least 10% of their body weight.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 250 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-09 · est. completion 2026-05

Where 72 sites · Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT06588283 ↗

Description as written by the study sponsor.

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.

Treatments tested

Ixekizumab also known as LY2439821 Drug

Administered SC
Tirzepatide also known as LY3298176 Drug

Administered SC.

Main thing measured	Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction
Sponsor	Eli Lilly and Company
Conditions studied	Psoriasis, Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06588283 ↗